Big Data Clinical Research Genome 
ACRP blog
JUNE 7, 2023
If you hadn’t already noticed, the clinical research enterprise has well and truly entered the era of “big data,” artificial intelligence (AI), and machine learning. It also includes search and support services that help patients understand, find, and enroll in clinical trials.”
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 15, 2023
Some of the medical advances with the technology are genomics and epigenetics, Big Data, AI and ML which are allowing molecular […] Technology adoptions like artificial intelligence and machine learning are bringing in major transformation in the way a primary physician will extend treatment protocols.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 16, 2022
Essentially, the collaboration brought together both “the right expertise and the right technology”, opening up myriad possibilities for targeting GPCRs within the human genome. A notable issue with clinical trials is the homogeneity of the patient database. What, then, is the solution? About the interviewee.
pharmaphorum
JULY 4, 2022
And this is where modern technologies and data-driven medical informatics can really bridge the gaps in rare disease research,” said Dr Joanne Hackett, head of Genomic and Precision Medicine at IQVIA, during a recent pharmaphorum webinar.
pharmaphorum
MARCH 16, 2021
International deep real-world evidence company Savana is on a mission to give health researchers the power to unlock the clinical value embedded within electronic health records (EHRs) using artificial intelligence (AI) and clinical Natural Language Processing (NLP) techniques.
The Pharma Data
JANUARY 17, 2021
Syntegra has also engaged with the Federal Drug Administration (FDA) to evaluate the role of synthetic data in regulatory decisions, for COVID-19 and beyond. With the COVID-19 pandemic, there has never been a time when rapid, low burden access to patient-level data, at scale, was more urgent” says Michael D. .
Expert insights. Personalized for you.
59 
Let's personalize your content